Matinas BioPharma joins NYSE
February 27, 2017Matinas BioPharma Holdings has been approved for listing on the New York stock exchange, and will be trading under the symbol “MTNB” starting from March 2, 2017. The company’s common stock will continue to trade on the OTCQB until the close of the market on March 1, 2017.
Matinas, a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, with this announcement makes an important step in its plan to increase shareholder value.
Roelof Rongen, Co-founder and Chief Executive Officer (CEO) of the company, said: “As we have advanced our business, clinical and regulatory strategies, we are rapidly approaching key data readouts for our lead anti-infective clinical development programs in the first and second quarters of this year.”
“We welcome Matinas BioPharma Holdings, Inc. to NYSE MKT, where it joins other innovative healthcare companies that take advantage of our market model combining leading technology and human oversight for listing and trading their shares,” said John Tuttle, NYSE Global Head of Listings.
” This transition greatly expands the pool of potential investors and comes with many other benefits as well,”said Jerome D. Jabbour, Co-founder and President of the Company.
